Dublin, Feb. 03, 2017 -- Research and Markets has announced the addition of the "Global Cell Therapy Market & Clinical Pipeline Outlook 2022" report to their offering.
The Global Cell Therapy Market & Clinical Pipeline Outlook 2022 report gives comprehensive insight on the ongoing clinical and nonclinical trends in the global cell therapy market.
Report analyzes the need and the application of cell therapy in multiple therapeutic areas along with the mechanism and delivery methods for cell therapy based treatment. The parameters impacting the growth of the market and the corresponding challenges limiting the commercialization of cell therapies are explained in the report.
The idea of cell therapy was in pharmaceutical industry for several decades but significant development was not made due to technological challenges. In recent years, cell therapy has gained widespread acceptance among physicians and patients due to its ability to treat various diseases. Several decades of research and development has allowed the investigators to come forth with solutions which can't be provided by conventional therapeutics. Theoretically, it could be used to cure plethora of diseases but underdeveloped technology has limited its usage to limited indications.
Several indications have been found to be curable with the help of cell therapies and indications are expected to be increased in near future. Cerebral disorders like Parkinson's disease and Alzheimer's disease are under investigation for treatment with the help of cell therapies. They are also being investigated for cardiovascular disease in which their aim is to restore normal heart functions. Investigators are also trying to find their safety and efficacy in treating various malignancies. On-going research is also aimed at curing metabolic disorder like diabetes mellitus type 1 in which patients tends to lack insulin production. Investigators are trying to restore the function of liver and kidney by supplementing them with modified cell of respective origins. Several clinical trials have been instigated across the globe in which their efficacy against different disease is being studies.
Global Cell Therapy Market & Clinical Pipeline Outlook 2022 Highlights:
- Introduction & Classification of Cell Therapies
- Mechanism of Cell Therapy
- Global Cell Therapy Market Analysis
- Role of Stem Cells in Cell Therapy
- Global Cell Therapy Clinical Pipeline by Country, Indication & Phase
- Global Cell Therapy Clinical Pipeline: 476
- Marketed Cell Therapies: 20
Key Topics Covered:
1. Introduction to Cell Therapy
2. Necessity for Cell Therapy Treatment
2.1 Emergence of Stem Cell Research
2.2 Benefits of Using the Stem Cell for Research & Treatment
3. Application of Stem Cells in Cell Therapy
3.1 Stem Cells Ability to Differentiate
3.1.1 Totipotent Stem Cells
3.1.2 Pluripotent Stem Cells
3.1.3 Multipotent Stem Cells
3.1.4 Unipotent Stem Cells
3.2 Origin of Stem Cells
3.2.1 Embryonic Stem Cells
3.2.2 Adult Stem Cells
3.2.3 Induced Pluripotent Stem Cells (iPSCs)
4. Applications of Cell Therapy by Therapeutic Area
4.1 Cell Therapy for Cardiovascular Diseases
4.2 Cell Therapy for Neurological Disorders
4.3 Cell Therapy for Inflammatory Diseases
4.4 Cell Therapy for Diabetes
4.5 Cell Therapy for Cancer
4.6 Cancer Stem Cells Therapy
5. Mechanism of Cell Therapy
5.1 Two Major Mechanism Principles of Stem Cell Based Therapy
5.2 Mechanism of Action in Alzheimer's Diseases
6. Delivery Method of Cell Based Therapy
6.1 Outline to Delivery Methods
6.2 Direct Delivery Methods
6.3 Indirect Delivery of the Cells by Using the Carrier
7. Mechanism of Cell Therapy Treatment
7.1 Allogeneic Stem Cell Therapy
7.2 Autologous Stem Cell Therapy
8. Global Cell Therapy Market Overview
8.1 Current Market Scenario
8.2 Current Trends of Cell Therapy in Global Market
8.3 Global Cell Therapies Clinical Pipeline Overview
9. Global Cell Therapy Market by Region
9.1 North America
9.2 Europe
9.3 Asia
9.4 Rest of the World
10. Global Cell Therapy Market Dynamics
10.1 Favorable Market Parameters
10.2 Factors Limiting Market Growth
11. Global Cell Therapy Market Future Prospect
12. Global Cell Therapies Clinical Pipeline by Company, Indication & Phase
12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase-0
12.6 Phase-I
12.7 Phase-I/II
12.8 Phase-II
12.9 Phase-II/III
12.10 Phase-III
12.11 Preregistration
12.12 Registered
13. Marketed Cell Therapies Clinical Insight by Company & Indication
13.1 T-Lymphocyte Cell Therapy (Immuncell-LC)
13.2 Muscle-Derived Autologous Stem Cell Therapy (MyoCell & MyoCell SDF-1)
13.3 Azficel-T (Laviv)
13.4 Sipuleucel-T (Provenge)
13.5 Placental Derived Mesenchymal Stem Cell Therapy - Osiris Therapeutics
13.6 Remestemcel-L (Prochymal & TEMCELL HS Inj.)
13.7 Autologous Mesenchymal Stem Cell Therapy - Pharmicell
13.8 Autologous Cultured Chondrocytes (MACI)
13.9 Mesenchymal Stem Cell Therapy for Cartilage Repair (Cartistem)
13.10 Leukocyte Cell Therapy (CureXcell)
13.11 Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem & Queencell)
13.12 Allogeneic Cultured Keratinocytes and Fibroblasts (Gintuit)
13.13 Autologous Cultured Chondrocyte Implant (Carticel)
13.14 Autologous Cultured Chondrocytes (CHONDRON)
13.15 Autologous Chondrocytes (BioCart & BioCartII)
13.16 Amniotic Cell Therapy (NuCel)
13.17 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical
13.18 Autologous Cultured Chondrocytes (Chondrotransplant DISC)
13.19 Autologous Cultured Myoblasts and Fibroblasts (Urocell)
13.20 Human Skin Replacement (CellSpray & CellSpray XP)
14. Competitive Landscape
14.1 AlloCure
14.2 Arteriocyte Medical Systems
14.3 Athersys Inc.
14.4 Baxter Healthcare Corporation
14.5 Bone Therapeutics
14.6 Celgene Corporation
14.7 Cell Medica
14.8 Cellerant Therapeutics
14.9 FibrocellScinence
14.10 Forticell Bioscience
14.11 Genzyme Corporation
14.12 Green Cross Cell
14.13 Histogenics Corporation
14.14 InnovacellBiotechnologie AG
14.15 Intrexon Corporation
14.16 Intercytex
14.17 ISTO Technologies
14.18 Macrocure
14.19 Mesoblast
14.20 Molmed
14.21 Nuo Therapeutics Inc
14.22 OmniCyte
14.23 Opexa Therapeutics
14.24 Organogenesis
14.25 Pharmicell
14.26 TCA Cellular Therapy
14.27 Stem Cell Inc.
14.28 Teva Pharmaceuticals
14.29 Tigenix
14.30 Vericel Corporation
For more information about this report visit http://www.researchandmarkets.com/research/m7mhfz/global_cell
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Genomics


OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 



